Publications by authors named "M Robertson-Tessi"
Article Synopsis
- Clinical trials by the Intergroup Rhabdomyosarcoma Study Group and the Children's Oncology Group have set the standards for diagnosing and treating rhabdomyosarcoma (RMS), but new biological insights complicate these processes.* -
- The rarity of RMS makes it difficult to conduct large phase 3 clinical trials, highlighting the need for careful planning to explore drug effectiveness, response markers, treatment toxicity, and patient quality of life.* -
- The Children's Oncology Group Soft Tissue Sarcoma Committee proposes a strategic plan for future RMS trials that includes identifying new agents, improving trial efficiency, expanding knowledge opportunities, reducing treatment toxicity, and enhancing patient engagement.*
ALL cures require many MRD therapies. This strategy should drive experiments and trials in metastatic bone sarcomas.
View Article and Find Full Text PDFToxicity and emerging drug resistance pose important challenges in poly-adenosine ribose polymerase inhibitor (PARPi) maintenance therapy of ovarian cancer. We propose that adaptive therapy, which dynamically reduces treatment based on the tumor dynamics, might alleviate both issues. Utilizing in vitro time-lapse microscopy and stepwise model selection, we calibrate and validate a differential equation mathematical model, which we leverage to test different plausible adaptive treatment schedules.
View Article and Find Full Text PDFIntroduction: Metabolism plays a complex role in the evolution of cancerous tumors, including inducing a multifaceted effect on the immune system to aid immune escape. Immune escape is, by definition, a collective phenomenon by requiring the presence of two cell types interacting in close proximity: tumor and immune. The microenvironmental context of these interactions is influenced by the dynamic process of blood vessel growth and remodelling, creating heterogeneous patches of well-vascularized tumor or acidic niches.
View Article and Find Full Text PDFArticle Synopsis
- Osteosarcoma, the most prevalent bone cancer in youth, shows variable responses to chemotherapy, with only about half of patients benefiting despite universal treatment.
- Researchers developed an in vitro model to study how different osteosarcoma cell lines, specifically 143B and SAOS2, respond to environmental and chemical changes, revealing significant variability in growth rates and drug sensitivity.
- Findings indicate that altering growth conditions can shift advantages between the cell lines, suggesting that exploring combinations of therapies could help overcome resistance in osteosarcoma treatment strategies.